Table 1.
Haemodynamic and prognostic data
| Time of presentation (/w dasatinib) | Time course under sildenafil (w/o dasatinib) | ||||
|---|---|---|---|---|---|
| Month: | 0 | +1 | + 3 | + 5 | + 7 |
| RVSP [mm Hg] | 73 | 51 | - | 17 | - |
| PAPmean [mm Hg] | 52 | - | - | - | 40 |
| PVR [dyn*s/cm-5] | 1250 | - | - | - | 356 |
| CO [l/min] | 1.7 | - | - | - | 4.7 |
| HR [/min] | 105 | - | - | - | 85 |
| proBNP [ng/l] | 27055 | 3037 | 1334 | 2076 | - |
| 6MWD [m] | 0 | 308 | 458 | - | - |
| WHO/NYHA FC | IV | II | I/II | II | II |
RVSP: right ventricular systolic pressure; PAPmean: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; CO: cardiac output; HR: heart rate; proBNP: brain natriuretic peptide propeptide; 6MWD: 6-minute walk distance; WHO/NYHA FC: World Health Organization/New York Heart Association functional class